Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.60 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14991641 | 0.85 | L3MBTL3 (0.74) | L3MBTL1L3MBTL4L3MBTL3HPGDSMN1; SMN2 | |
| SCHEMBL1964003 | 0.85 | L3MBTL4 (0.69) | L3MBTL1L3MBTL4L3MBTL3HPGDSMN1; SMN2 | |
| SCHEMBL2375421 | 0.85 | L3MBTL4 (0.58) | L3MBTL1L3MBTL4L3MBTL3HPGDSMN1; SMN2 | |
| SCHEMBL18734159 | 0.84 | L3MBTL3 (0.72) | L3MBTL1L3MBTL4L3MBTL3HPGDSMN1; SMN2 | |
| SCHEMBL12751719 | 0.82 | L3MBTL4 (0.69) | L3MBTL1L3MBTL4L3MBTL3HPGDSMN1; SMN2 | |
| SCHEMBL1558959 | 0.81 | ALDH1A1 (0.72) | L3MBTL1L3MBTL4L3MBTL3HPGDSMN1; SMN2 | |
| SCHEMBL27402476 | 0.81 | L3MBTL4 (0.60) | L3MBTL1L3MBTL4L3MBTL3HPGDSMN1; SMN2 | |
| SCHEMBL25975340 | 0.81 | KMT2A (0.48) | L3MBTL1HPGDKDM4EPOLBALPL | |
| SCHEMBL30961632 | 0.81 | L3MBTL4 (0.60) | L3MBTL1L3MBTL4L3MBTL3HPGDSMN1; SMN2 | |
| SCHEMBL15229234 | 0.80 | L3MBTL4 (0.53) | L3MBTL1L3MBTL4L3MBTL3HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605089-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | Mekanistic Therapeutics LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024086296-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | MEKANISTIC THERAPEUTICS LLC (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-9434743-B2 | Indazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-06 | — | — | US | disclosed |
| US-9434743-B2 | Indazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-06 | — | — | US | disclosed |
| US-9434743-B2 | Indazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-06 | — | — | US | disclosed |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2013130855-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130855-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-06 | — | — | WO | disclosed |
| CN-101501035-B | Pyrimidine derivatives as PI3K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD | 2013-01-23 | — | — | CN | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| CN-101501035-A | Pyrimidine derivatives as P13K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005232-A1 | INDAZOLE DERIVATIVES | GPR119, INSR, INSRR | L3MBTL1 1844/4885L3MBTL4 3166/4885L3MBTL3 2067/4885 |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | L3MBTL1 2077/4885L3MBTL4 3038/4885L3MBTL3 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.